Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity
about
Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MSLaquinimod for multiple sclerosisLaquinimod for multiple sclerosisLaquinimod in the treatment of multiple sclerosis: a review of the data so farKynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous SystemLupus nephritis: the evolving role of novel therapeuticsLaquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic ImplicationsBPIQ, a novel synthetic quinoline derivative, inhibits growth and induces mitochondrial apoptosis of lung cancer cells in vitro and in zebrafish xenograft modelTherapeutic decisions in multiple sclerosis: moving beyond efficacyDual roles of extracellular signal-regulated kinase (ERK) in quinoline compound BPIQ-induced apoptosis and anti-migration of human non-small cell lung cancer cellsEfficacy and safety of laquinimod in multiple sclerosis: current statusLaquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.Laquinimod in the treatment of relapsing remitting multiple sclerosis.Dynamic regulation of serum aryl hydrocarbon receptor agonists in MSDefining a role for laquinimod in multiple sclerosis.Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.Role and therapeutic value of dendritic cells in central nervous system autoimmunity.Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple SclerosisY27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice.Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptorAntiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis.Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases.Teriflunomide and its mechanism of action in multiple sclerosis.JNK inhibitors as anti-inflammatory and neuroprotective agents.Review of laquinimod and its therapeutic potential in multiple sclerosis.The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosisDendritic cells as therapeutic targets in neuroinflammation.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Myeloid cells - targets of medication in multiple sclerosis.Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
P2860
Q22251014-085A7E42-64C4-45B7-A59E-5873E8A17D34Q24198180-B58C3AEC-F4F4-4E80-A395-F5DC3CAF3EB3Q24200527-A682ED59-5397-4790-80AD-8F0D8A7DB3DDQ26752895-89720BDA-37F6-41B4-A1AC-200041F31817Q26796667-95B58975-8D1F-4A2B-B6BD-201A51323B76Q26998390-009B2081-69F1-4697-B267-90AD2C44F347Q27316866-5CA0B837-2578-4C89-8095-92B84CF8F417Q28078299-2907CA46-515A-4A4F-A4D0-5925D86C606AQ28396577-D396C3E2-5F45-45F7-9A0F-802C121E987EQ28541039-F3590D2D-D0B7-46BA-913B-520534373039Q29248583-186D2DD8-3813-4186-A6C5-9F8ADE87677DQ30694702-43CAB6F5-A78F-4457-8954-1B07F9DCE011Q31017620-3E9A7F0F-254A-45C5-A2BB-869B4C3699AFQ31080085-72AB6405-DB7C-4CA6-B91D-E1264C6A3BA7Q33808285-1FE6F14F-A5B2-4899-89D0-E515BA937D7DQ33847350-329E8199-B250-458C-8C5A-9A4E71126C0AQ33988247-4E2AFAFD-87B3-4663-B523-1FC3E3221791Q34286754-78532CE6-6C0C-4EFD-9A53-7B39DA86E424Q34332609-21BE7D5E-8988-4A50-AF45-9DBF52B0E13BQ34924088-9E6B39F8-3AAD-4FDF-9A72-F91E35783C00Q35648000-8CF146B2-3A97-47AB-A195-A07919E95726Q36174480-614EF0EF-7790-4A3A-9403-16548465C143Q36407218-642A3671-DB58-4516-919D-C6F97A2FE687Q36907746-650D1EEC-A5D6-4919-927F-372811E0BAD6Q37169655-D16F065A-01C3-4562-83CB-27B53BF6E349Q37274895-AED43760-02B8-4528-A94F-84E7F1821DA1Q37346761-1ED28524-DB39-482A-A420-0B8B48849649Q37576708-D785ACC3-C595-4031-B54D-A3662624DC9EQ37603419-E35F2069-247F-49B8-8736-44A361D94025Q37670027-011E9E08-A946-44A9-B5D6-6CF460A78831Q37730005-2E40EBDC-E1EC-40A9-8D2E-43A481410910Q38097866-26E10987-31C2-4DB4-A6BE-F6C0FFF9EC7DQ38161575-EAB9A9F9-5DFD-4A67-B112-3114F2C8E532Q38186206-332471DF-08B5-45D3-9173-B0C98E5AF98BQ38216015-CDFFDE3F-FD87-462A-8A67-3C978F1AB19FQ38771884-87BE008E-F1EE-425A-8490-1BD3FD942F86Q38837294-856162AC-3FD1-4872-88DC-B470C7072F94Q38924828-23496DCD-AC6B-4252-81C6-F86F90F01A2BQ39244069-566EF93C-BBFF-44E0-AEDB-D44D818ECFA9Q39447177-CA8F704C-B60A-4EA5-9791-AA77B602AA0F
P2860
Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Laquinimod, a quinoline-3-carb ...... al nervous system autoimmunity
@ast
Laquinimod, a quinoline-3-carb ...... al nervous system autoimmunity
@en
Laquinimod, a quinoline-3-carb ...... al nervous system autoimmunity
@nl
type
label
Laquinimod, a quinoline-3-carb ...... al nervous system autoimmunity
@ast
Laquinimod, a quinoline-3-carb ...... al nervous system autoimmunity
@en
Laquinimod, a quinoline-3-carb ...... al nervous system autoimmunity
@nl
prefLabel
Laquinimod, a quinoline-3-carb ...... al nervous system autoimmunity
@ast
Laquinimod, a quinoline-3-carb ...... al nervous system autoimmunity
@en
Laquinimod, a quinoline-3-carb ...... al nervous system autoimmunity
@nl
P2093
P2860
P3181
P1433
P1476
Laquinimod, a quinoline-3-carb ...... al nervous system autoimmunity
@en
P2093
Aparna Shetty
Michel Varrin-Doyer
Nicolas Molnarfi
Patricia A Nelson
Raymond A Sobel
Scott S Zamvil
Sharon A Sagan
Ulf Schulze-Topphoff
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0033797
P407
P577
2012-01-01T00:00:00Z